Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.


Journal

Przeglad epidemiologiczny
ISSN: 0033-2100
Titre abrégé: Przegl Epidemiol
Pays: Poland
ID NLM: 0413725

Informations de publication

Date de publication:
2020
Historique:
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 11 11 2020
Statut: ppublish

Résumé

Around the end of December 2019, a new beta-coronavirus from Wuhan City, Hubei Province, China began to spread rapidly. The new virus, called SARS-CoV-2, which could be transmitted through respiratory droplets, had a range of mild to severe symptoms, from simple cold in some cases to death in others. The disease caused by SARS-CoV-2 was named COVID-19 by WHO and has so far killed more people than SARS and MERS. Following the widespread global outbreak of COVID-19, with more than 132758 confirmed cases and 4955 deaths worldwide, the World Health Organization declared COVID-19 a pandemic disease in January 2020. Earlier studies on viral pneumonia epidemics has shown that pregnant women are at greater risk than others. During pregnancy, the pregnant woman is more prone to infectious diseases. Research on both SARS-CoV and MERS-CoV, which are pathologically similar to SARS-CoV-2, has shown that being infected with these viruses during pregnancy increases the risk of maternal death, stillbirth, intrauterine growth retardation and, preterm delivery. With the exponential increase in cases of COVID-19 throughout the world, there is a need to understand the effects of SARS-CoV-2 on the health of pregnant women, through extrapolation of earlier studies that have been conducted on pregnant women infected with SARS-CoV, and MERS-CoV. There is an urgent need to understand the chance of vertical transmission of SARS-CoV-2 from mother to fetus and the possibility of the virus crossing the placental barrier. Additionally, since some viral diseases and antiviral drugs may have a negative impact on the mother and fetus, in which case, pregnant women need special attention for the prevention, diagnosis, and treatment of COVID-19.

Identifiants

pubmed: 33112124
doi: 10.32394/pe.74.21
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

276-289

Informations de copyright

© National Institute of Public Health – National Institute of Hygiene.

Déclaration de conflit d'intérêts

The authors confirm that they have no conflicts of interest.

Auteurs

Mobina Fathi (M)

Student's Research committee, School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Kimia Vakili (K)

Student's Research committee, School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Niloofar Deravi (N)

Student's Research committee, School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Shirin Yaghoobpoor (S)

Student's Research committee, School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Elahe Ahsan (E)

Student's Research committee, School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Melika Mokhtari (M)

Student research committee, Faculty of dentistry, Tehran Medical sciences, Islamic Azad university, Tehran, Iran.

Maryam Moshfeghi (M)

Royan Institute - Department of Endocrinology and Female Infertility,Reproductive Biomedicine, Research Center, ACECR, Tehran, Iran.

Maryam Vaezjalali (M)

Department of Microbiology, Faculty of Medicine, Shahid Beheshti University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH